An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies

Trial Profile

An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Idelalisib (Primary) ; Antineoplastics; Immunotherapies
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 03 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
    • 03 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top